Swisse Identifies Hormonal Health, Perimenopause as Key Growth Sectors for Women's Supplements
H&H Group's Swisse brand highlights significant innovation opportunities and unmet consumer needs within hormonal health and perimenopause, driven by biochemical volatility and a high symptom prevalence among women aged 35+. This signals a strategic focus on targeted product development and ingredient R&D.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Singapore, Singapore — 13 August 2026
H&H Group's Swisse brand is strategically prioritising hormonal health and perimenopause support within its women's health portfolio, identifying these areas as critical for innovation and market growth. Dr Novita Puspasari, Scientific Affairs Manager at H&H Group, underscored that women's health is a continuous journey presenting significant opportunities for targeted product solutions. Her insights, shared at the recent Growth Asia Summit, position hormonal modulation as a key lens for effective product development.
Dr Puspasari characterised perimenopause as a 'window of vulnerability' marked by rapidly fluctuating ovarian hormones, which interact with the hypothalamic-pituitary-adrenal (HPA) stress axis, increasing stress sensitivity. This biochemical volatility can lead to up to 60 distinct symptoms, including hot flashes, sleep disturbances, night sweats, brain fog, and mood swings. H&H's data indicates that one in three women aged 35 and above currently experience perimenopausal or menopausal symptoms, with 49% reporting mild symptoms and 38% moderate symptoms, signalling a substantial and largely unmet consumer need.
Despite the clear market opportunity, Dr Puspasari highlighted a significant gap between current research and product innovation. She noted a specific lack of clinically trialled ingredients proven effective for women across specific life stages, particularly for perimenopausal symptoms. This deficiency necessitates increased investment in research and development from both ingredient suppliers and brand owners to formulate more effective, targeted solutions. Adaptogens, such as ashwagandha, are gaining prominence for their ability to manage stress and restore homeostasis, addressing symptoms linked to HPA axis dysregulation.
Swisse Ultiboost Perimenopause Balance exemplifies this strategic direction. The product features KSM-66, a high-concentration ashwagandha extract, targeting hormonal modulation (estradiol, follicle-stimulating hormone) and HPA axis regulation. Clinical evidence supports KSM-66's efficacy in managing hot flashes, night sweats, irritability, and sleeplessness in perimenopausal women, establishing a precedent for evidence-backed product claims within this category.
What this means for United Kingdom
UK supplement manufacturers and brand owners must recognise the burgeoning demand for perimenopause-specific formulations. Brands should assess current ingredient portfolios for clinically validated adaptogens or botanicals with proven efficacy against specific perimenopausal symptoms, such as KSM-66 ashwagandha. Regulatory teams must ensure all claims adhere strictly to UK ASA guidelines, particularly regarding hormone balance and symptom management, backed by robust human clinical data. This segment offers a significant opportunity for market differentiation and premiumisation, potentially commanding higher price points with effective, evidence-based products, provided reformulation windows can align with market entry demands.
Many leading brands in this category are manufactured in partnership with Supplement Factory.